Ultrafast 30‐min infusion of a rituximab biosimilar (Truxima)

In this clinical trial, we demonstrate that ultrarapid fast infusion of rituximab (Truxima) in 30 min with oral premedication is feasible and secure for patients, and reduce the day‐care hospital stays.

Detalles Bibliográficos
Autores principales: Pérez‐Persona, Ernesto, Cuevas Palomares, Laida, Unamunzaga Cilaurren, Ariane, Gutiérrez López de Ocáriz, Xabier, Buendía Ureña, Buenaventura, Vega González de Viñaspre, Ana, Benito Ibarrondo, Begoña, Molinillo Fernández, María Carmen, Cordero Osúa, Ana, Benítez Delgado, Beatriz, García Albás, Juan José, Andrés Moralejo, Miguel Ángel, Guinea de Castro, José María
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660389/
https://www.ncbi.nlm.nih.gov/pubmed/38024594
http://dx.doi.org/10.1002/jha2.812
Descripción
Sumario:In this clinical trial, we demonstrate that ultrarapid fast infusion of rituximab (Truxima) in 30 min with oral premedication is feasible and secure for patients, and reduce the day‐care hospital stays.

Ejemplares similares